Business Wire

Lattice Sentry Solutions Stack 2.0 Enhances Cyber Resiliency with New Expanded Capabilities

2.3.2021 00:00:00 EET | Business Wire | Press release

Share

As the next step in its ongoing mission to deliver secure, cyber-resilient system control solutions, Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today announced the latest version of its solutions stack for secure system control, Lattice Sentry™ 2.0. The solutions stack enables next-generation hardware Root-of-Trust (HRoT) solutions compliant with NIST Platform Firmware Resiliency (PFR) Guidelines (NIST SP-800-193) and supporting 384-bit encryption. This new version of Lattice Sentry addresses the rapidly evolving security requirements of current and emerging server platforms by providing developers an efficient and secure way to quickly implement enhanced system and cryptographic applications. The stack supports firmware security for the communications, computing, industrial, automotive, and smart consumer markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005143/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Lattice Sentry solutions stack helps developers create cyber resilient system control applications compliant with NIST guidelines for platform firmware security (NIST SP-800-193). It consists of a complete reference platform, fully validated IP building blocks, easy-to-use FPGA design tools, reference designs, and a network of custom design services. (Photo: Business Wire)

The Cloud Security Industry Summit (CSIS) is a group of cloud service providers working towards industry alignment on best-of-breed security solutions. In a whitepaper jointly authored with the Open Compute Project (OCP), CSIS said, “Firmware represents a significant threat vector for computer systems, appliances, and associated infrastructure. If the first code that executes on a device when it powers on were to become compromised, then the entire system can and should no longer be trusted as secure. Firmware can be compromised through malicious attacks or unintentionally.”1

“Staying on top of evolving cybersecurity threats is a constant struggle for most organizations. To help them keep pace, Lattice is committed to the ongoing improvement of the security, performance, and ease-of-use capabilities of our Sentry stack,” said Eric Sivertson, Vice President of Security Business, Lattice Semiconductor. “Lattice is a long-time leader in server control solutions, and Lattice control PLDs are the first-on/last-off component in many servers currently in service. With the Sentry stack, developers can easily add support for strong firmware security to system control applications based on Lattice secure control PLDs, creating an ideal platform to establish a HRoT to validate the legitimacy of all firmware instances in a system.”

Key features for Sentry 2.0 include:

  • Heightened security – The Sentry solutions stack supports the Lattice Mach™-NX secure control FPGA and a secure enclave IP block that enable 384-bit cryptography (ECC-256/384 and HMAC-SHA-384) to better secure Sentry-protected firmware against unauthorized access. Support for 384-bit crypto is a requirement for many next-generation server platforms.
  • 4x faster pre-boot authentication – Sentry 2.0 supports faster ECDSA (40 ms), SHA (up to 70 Mbps), and QSPI performance (64 MHz). These features enable Sentry 2.0 to deliver faster boot times that help minimize system down time and reduce exposure to attempted attacks on firmware during the boot process.
  • Ability to monitor up to five firmware images in real-time – To further extend the PFR-compliant HRoT enabled by Lattice Sentry, the stack is capable of real-time monitoring of up to five mainboard components in a system at boot and during ongoing operation. Competing MCU-based security solutions, as an example, lack the processing performance to properly monitor that many components in real-time.

For more information about the Lattice products mentioned above, please visit:

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo, or Youku.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

1 https://www.opencompute.org/documents/csis-firmware-security-best-practices-position-paper-version-1-0-pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Bob Nelson
Lattice Semiconductor
408-826-6339
Bob.Nelson@latticesemi.com

INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye